- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03771638
DOT Diary Mobile App for Pre-Exposure Prophylaxis Adherence in Young Men
DOT Diary Longitudinal Pilot: A Mobile App for Pre-Exposure Prophylaxis Adherence in Young Men
Study Overview
Status
Intervention / Treatment
Detailed Description
In the DOT Diary research project, the AiCure automated directly observed therapy (aDOT) smartphone app has been adapted for use in monitoring and supporting HIV pre-exposure prophylaxis (PrEP) use among young men who have sex with men (YMSM). The aDOT app uses automated directly observed therapy (DOT) that use the smartphone camera and artificial intelligence software to confirm that the right person is taking the right medication at the right time. A sexual diary has been integrated into the aDOT app to assist YMSM in understanding whether they are receiving protection from PrEP for individual sexual episodes, and when it is particularly important to take PrEP (e.g. after a sexual episode). Specifically, the sexual diary allows participants to track sexual encounters, sexual behaviors that occurred in each encounter, and rating characteristics of partners. The app provides a calendar displaying all days in which PrEP medication was taken, and all days in which sexual activity occurred, allowing participants to see coverage of sexual encounters with PrEP. Based on pharmacokinetic and pharmacodynamic data from prior PrEP trials, the app will also indicate the estimated level of protection achieved from PrEP (e.g. low, medium, high), and also provide personalized messages on the additional numbers of doses needed to maximize protection.
In the next stage of app development and assessment, the researchers will conduct the DOT Diary Longitudinal Pilot to assess the impact of the app on PrEP adherence as measured by pharmacokinetic measures of PrEP use (tenofovir diphosphate [TFV-DP] and emtricitabine triphosphate [FTC-TP] levels in dried blood spots [DBS]). The researchers will also assess the concordance of TFV-DP and FTC-TP in DBS with adherence measured by DOT Diary, and the acceptability and ease of use of the app over a longer (24-week) period. This pilot study will allow evaluation and further refinement of the app in preparation for testing in a larger efficacy trial among YMSM at risk for HIV acquisition. The researchers will conduct this pilot protocol among YMSM in Atlanta and San Francisco Bay Area, two metropolitan regions heavily impacted by HIV, yet differing in sociodemographics, as well as in the availability and uptake of HIV prevention services, including PrEP. These diverse research locations will allow collection of data to inform app development among a broad group of YMSM.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94102
- Bridge HIV, San Francisco Department of Public Health
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University, School of Public Health
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Self-identifies as a man
- Age 18-35 at enrollment
Reports having insertive or receptive anal sex with a man or trans woman in the past 12 months and one or more of the following criteria in the last 12 months:
- Any condomless anal sex outside of a mutually monogamous relationship with an HIV-negative partner
- Two or more anal sex partners
- Self-reported sexually transmitted infection (STI; gonorrhea, chlamydia, syphilis)
- Having a known HIV-positive sexual partner
- HIV-negative as determined by a negative 4th generation HIV test at screening and negative rapid 4th generation test at enrollment
- Willing to initiate PrEP
Eligible to take PrEP
- Creatinine clearance ≥60 ml/min as estimated by Cockcroft-Gault equation at screening
- Hepatitis B surface antigen (HBsAg) negative
- Willing and able to provide written informed consent
- Able to read and speak English
- Smartphone ownership compatible with DOT Diary app
- Meets local locator requirements
- Lives, works or plays in Atlanta Metropolitan Area, San Francisco, Alameda, Marin, Contra Costa, Santa Clara, or San Mateo Counties
Exclusion Criteria:
- PrEP use within the past 4 months (PrEP naive participants will be prioritized)
- Any reactive HIV test at screening or enrollment
- Signs or symptoms of acute HIV infection at screening or enrollment
- History of pathological bone fracture not related to trauma
- Taking nephrotoxic medications
- History of participation in the active arm of an HIV vaccine trial
- In a mutually monogamous sexual relationship with an HIV-negative partner for the past 12 months
- Unable to commit to study participation for 24 weeks
- Any medical, psychiatric, or social condition or other responsibilities that, in the judgment of the investigator, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: DOT Diary Intervention
DOT Diary mobile app and Emtricitabine / Tenofovir Disoproxil Oral Tablet (once daily)
|
Open label daily emtricitabine/tenofovir disoproxil oral tablet
Other Names:
DOT Diary mobile application for tracking medication adherence and sexual activities.
|
OTHER: DOT Diary Control
Standard of care for Emtricitabine / Tenofovir Disoproxil Oral Tablet (once daily)
|
Open label daily emtricitabine/tenofovir disoproxil oral tablet
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effect of DOT Diary app on PrEP adherence
Time Frame: 24 weeks
|
Measurement of PrEP Adherence as measured by TFV-DP in DBS among young MSM initiating PrEP
|
24 weeks
|
Concordance of TFV-DP and FTC-TP in DBS with adherence measured by DOT Diary app
Time Frame: 24 weeks
|
Validation of DOT will focus on concordance between aDOT-based assessments of PrEP adherence by the DOT Diary app with DBS measurements
|
24 weeks
|
DOT Diary mobile app acceptability
Time Frame: 24 weeks
|
Combined descriptive analysis of key attributes of acceptability of DOT Diary over 24 weeks by YMSM on PrEP, in order to identify potential improvements to the app to maximize acceptability
|
24 weeks
|
DOT Diary mobile app ease of use
Time Frame: 24 weeks
|
Combined descriptive analysis of key attributes of ease of use of DOT Diary over 24 weeks by YMSM on PrEP
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PrEP coverage of sexual acts (prevention-effectiveness adherence) as measured by DOT Diary
Time Frame: 24 weeks
|
Combined analysis of the probability of coverage of condomless receptive sexual acts in each period with sexual acts treated as trials, and coverage as success.
|
24 weeks
|
Evaluation of daily use of aDOT components of DOT Diary app
Time Frame: 24 weeks
|
Estimation of the average use of aDOT components, as proportion of days on study
|
24 weeks
|
Evaluation of use of diary components of DOT Diary app
Time Frame: 24 weeks
|
Estimation of the average use of diary component of DOT Diary app as proportions of weeks on study.
|
24 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Susan Buchbinder, MD, Bridge HIV, San Francisco Department of Public Health
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18-25821
- 1R01MH109320-01 (NIH)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Risk Behavior
-
Bournemouth UniversityDorset HealthCare University NHS Foundation TrustWithdrawnRisk Behavior | Violence | Risk Behavior, Health
-
Rhode Island HospitalEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedRisk Behavior | Risk Reduction | Emotion RegulationUnited States
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI)CompletedHealth Behavior | Risk Reduction BehaviorUnited States
-
University of Colorado, DenverSmith-Richardson FoundationCompletedRisk Reduction Behavior | Reproductive BehaviorUnited States
-
University of MiamiEnrolling by invitation
-
Ginger YangUniversity of IowaRecruitingRisk Behavior | Adolescent Behavior | DriveUnited States
-
Pro-Change Behavior SystemsCommunity Health Center, Inc.Unknown
-
University of UtahNational Institute of Environmental Health Sciences (NIEHS)RecruitingRisk Reduction | Environmental Exposure | Risk Behavior, HealthUnited States
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)RecruitingBehavior, RiskUnited States
-
Lehigh UniversityAlliance of Border Collaboratives; Programa CompañerosUnknownRisk BehaviorUnited States, Mexico
Clinical Trials on Emtricitabine / Tenofovir Disoproxil Oral Tablet
-
Eastern Virginia Medical SchoolGilead Sciences; United States Agency for International Development (USAID); FHI... and other collaboratorsActive, not recruitingAdherence, Medication | Acceptability of Health CareSouth Africa, Zimbabwe
-
University of California, San DiegoActive, not recruitingHiv | Hormone TherapyUnited States
-
Hospitales Universitarios Virgen del RocíoInstituto de Biomedicina de SevillaEnrolling by invitationHepatitis, Viral, Human | HIV Infection Primary | Sexually Transmitted Infections, Excluding HIV and HepatitisSpain
-
National Institute of Allergy and Infectious Diseases...Microbicide Trials NetworkCompleted
-
University of Colorado, DenverCompletedHealthy Volunteers | Pharmacokinetics
-
National Institute of Allergy and Infectious Diseases...Microbicide Trials NetworkCompletedHIV InfectionsSouth Africa, Uganda, Zimbabwe
-
Professor Francois VenterCompletedHIV-1 InfectionSouth Africa
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedHIV InfectionsUnited States, Puerto Rico
-
University of ChicagoPlanned Parenthood Great PlainsWithdrawn
-
Rhonda BrandNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV | Medication AdherenceUnited States